Press Releases

Coya Therapeutics announced the execution of an option agreement for exclusive worldwide rights to a novel and proprietary technology platform enabling...

Creative Biolabs expands exosome engineering services for wider applications, especially for loading cargo into exosomes and targeting delivery. Exosomes have been acknowledged as promising natural carriers for drug loading and delivery, mainly due to their biological characteristics of intercellular communicator ...

Coya Therapeutics, a clinical-stage biotechnology company developing multiple first-in-class and best-in-class approaches that enhance regulatory T cell (Treg) function, today announced that it has raised approximately $10.3 million from institutional and...

Mercy BioAnalytics, a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced that the Mercy Halo Ovarian Cancer (OC) assay substantially outperformed...

Evox Therapeutics, a leading exosome therapeutics company, announced advances in exosome engineering, manufacturing and tissue targeting at the International Society for Extracellular Vesicles (ISEV) Annual Meeting, on May 25 to 29, 2022, in Lyon...

Predicine, a global molecular insights company, today announced the results of a new research study that demonstrated superior performance of the PredicineATLAS™ liquid biopsy next-generation...

VivaZome Therapeutics announced that it has entered into a Memorandum of Understanding (MoU) with The University of Queensland (UQ) focusing on improved therapies for Traumatic Brain Injury...

ExoCoBio, one of global top 4 for stem cell exosome industry, announced that it received from Japanese Patent Office the patent which claims that stem cell-derived exosome is proved as effective ingredient for...

Vitti Labs, an AATB Accredited Tissue Bank focused on life Science Research, development, and manufacturing, announced today that the U.S. Food and Drug Administration (FDA) has approved their...

RoosterBio’s MSC-derived exosome bioprocess technology platform enables accelerated development of ShiftBio’s lead therapeutic candidate via a scalable cGMP manufacturing process in bioreactors, downstream purification, and analytical characterization...